For: | Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20(11): 2955-2961 [PMID: 24659886 DOI: 10.3748/wjg.v20.i11.2955] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i11/2955.htm |
Number | Citing Articles |
1 |
Tomomi Kogiso, Katsutoshi Tokushige. Key roles of hepatologists in successful liver transplantation. Hepatology Research 2018; 48(8): 608 doi: 10.1111/hepr.13183
|
2 |
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatology Research 2020; 50(8): 892 doi: 10.1111/hepr.13504
|
3 |
Philippe Gallay, Daren Ure, Michael Bobardt, Udayan Chatterji, James Ou, Daniel Trepanier, Robert Foster, Haitao Guo. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLOS ONE 2019; 14(6): e0217433 doi: 10.1371/journal.pone.0217433
|
4 |
Kazuhiro Murai, Hayato Hikita, Yugo Kai, Yasuteru Kondo, Makoto Fukuoka, Keisuke Fukutomi, Akira Doi, Takuo Yamai, Tasuku Nakabori, Ryo Fukuda, Takeshi Takahashi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara. Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-57603-9
|
5 |
Satomi Shimura, Koichi Watashi, Kento Fukano, Michael Peel, Ann Sluder, Fumihiro Kawai, Masashi Iwamoto, Senko Tsukuda, Junko S. Takeuchi, Takeshi Miyake, Masaya Sugiyama, Yuki Ogasawara, Sam-Yong Park, Yasuhito Tanaka, Hiroyuki Kusuhara, Masashi Mizokami, Camille Sureau, Takaji Wakita. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. Journal of Hepatology 2017; 66(4): 685 doi: 10.1016/j.jhep.2016.11.009
|
6 |
Alberto Frosi, Maria Franca Meloni, Giacomo Frosi. Cluster of hepatitis C in a family: a twenty-year follow-up. Central European Journal of Public Health 2019; 27(2): 170 doi: 10.21101/cejph.a5027
|
7 |
Edward J Gane, Robert H Hyland, Di An, Evguenia S Svarovskaia, Diana Brainard, John G McHutchison. Ledipasvir and Sofosbuvir for HCV Infection in Patients Coinfected with HBV. Antiviral Therapy 2016; 21(7): 605 doi: 10.3851/IMP3066
|
8 |
Senko Tsukuda, Koichi Watashi, Taichi Hojima, Masanori Isogawa, Masashi Iwamoto, Katsumi Omagari, Ryosuke Suzuki, Hideki Aizaki, Soichi Kojima, Masaya Sugiyama, Akiko Saito, Yasuhito Tanaka, Masashi Mizokami, Camille Sureau, Takaji Wakita. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology 2017; 65(4): 1104 doi: 10.1002/hep.28952
|
9 |
S. K. Sarin, M. Kumar, G. K. Lau, Z. Abbas, H. L. Y. Chan, C. J. Chen, D. S. Chen, H. L. Chen, P. J. Chen, R. N. Chien, A. K. Dokmeci, Ed Gane, J. L. Hou, W. Jafri, J. Jia, J. H. Kim, C. L. Lai, H. C. Lee, S. G. Lim, C. J. Liu, S. Locarnini, M. Al Mahtab, R. Mohamed, M. Omata, J. Park, T. Piratvisuth, B. C. Sharma, J. Sollano, F. S. Wang, L. Wei, M. F. Yuen, S. S. Zheng, J. H. Kao. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International 2016; 10(1): 1 doi: 10.1007/s12072-015-9675-4
|
10 |
Andrea Martins Melo Fontenele, Juliana Braga Furtado Gainer, Daniel Viana da Silva e Silva, Max Diego Cruz Santos, João Victor Salgado, Natalino Salgado Filho, Adalgisa Sousa Paiva Ferreira. Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil. Hemodialysis International 2015; 19(3): 353 doi: 10.1111/hdi.12285
|
11 |
Sunil S. Solomon, Aylur K. Srikrishnan, Allison M. McFall, M. Suresh Kumar, Shanmugam Saravanan, Pachamuthu Balakrishnan, Suniti Solomon, David L. Thomas, Mark S. Sulkowski, Shruti H. Mehta, Anand S Mehta. Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India. PLOS ONE 2016; 11(1): e0147879 doi: 10.1371/journal.pone.0147879
|
12 |
Masashi Iwamoto, Koichi Watashi. Closing the Door On Hepatitis B and D Virus Entry: What are Our Therapeutic options?. Future Virology 2016; 11(11): 715 doi: 10.2217/fvl-2016-0097
|
13 |
Qin Ning, Ting Wu, Hai-Bin Su, Ke Ma, Jun-Ying Qi, Ming Ni, Di Wu. Acute Exacerbation of Chronic Hepatitis B. 2019; : 371 doi: 10.1007/978-94-024-1603-9_5
|
14 |
Heather L. Stevenson, Netanya S. Utay. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Tropical Diseases, Travel Medicine and Vaccines 2016; 2(1) doi: 10.1186/s40794-016-0038-5
|
15 |
Carla S. Coffin, Norah A. Terrault. Hepatitis B Virus and Liver Disease. 2018; : 239 doi: 10.1007/978-981-10-4843-2_13
|
16 |
Lee-Won Chong, Chih-Chao Hsu, Chang-Yin Lee, Ruey-Hwang Chou, Cheng-Li Lin, Kuang-Hsi Chang, Yi-Chao Hsu. Association of viral hepatitis and bipolar disorder: a nationwide population-based study. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1542-3
|
17 |
Kimberly A. Toussaint-Miller, Jennifer Andres. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Annals of Pharmacotherapy 2015; 49(9): 1015 doi: 10.1177/1060028015592015
|
18 |
Jamil A. Al‐Mughales. Co‐infection assessment in HBV, HCV, and HIV patients in Western Saudi Arabia. Journal of Medical Virology 2016; 88(9): 1545 doi: 10.1002/jmv.24503
|